{"id":"https://openalex.org/W4232284669","doi":"https://doi.org/10.1001/jama.1997.03550020057038","title":"Safety and Efficacy of Pramipexole in Early Parkinson Disease: A Randomized Dose-Ranging Study","display_name":"Safety and Efficacy of Pramipexole in Early Parkinson Disease: A Randomized Dose-Ranging Study","alternate_titles":[],"publication_year":1997,"publication_date":"1997-07-09","ids":{"openalex":"https://openalex.org/W4232284669","doi":"https://doi.org/10.1001/jama.1997.03550020057038","pmid":"https://pubmed.ncbi.nlm.nih.gov/9214527"},"language":"en","primary_location":{"id":"doi:10.1001/jama.1997.03550020057038","doi":"https://doi.org/10.1001/jama.1997.03550020057038","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jama.1997.03550020057038","pdf_url":null,"source":{"id":"https://openalex.org/S172573765","display_name":"JAMA","issn_l":"0002-9955","issn":["0002-9955","0098-7484","1538-3598","2376-8118"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"journal-article"},"parent_works":[],"lineage":["https://openalex.org/W4232284669"],"child_works_count":0,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[],"institutions":[],"countries_distinct_count":0,"institutions_distinct_count":0,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":12.7766,"has_fulltext":false,"cited_by_count":220,"reviewed_by_count":0,"citation_normalized_percentile":{"value":0.99135168,"is_in_top_1_percent":true,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"278","issue":"2","first_page":"125","last_page":"125"},"is_retracted":false,"is_pulled":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10919","display_name":"Deep Brain Stimulation and Movement Disorders","score":0.0003000000142492354,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T13991","display_name":"Nuclear Receptors and Signaling","score":0.0,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/pramipexole","display_name":"pramipexole","score":0.9729999899864197},{"id":"https://openalex.org/keywords/parkinson-s-disease","display_name":"Parkinson's disease","score":0.7990000247955322},{"id":"https://openalex.org/keywords/early-parkinson-s-disease","display_name":"early-stage Parkinson's disease","score":0.8050000071525574},{"id":"https://openalex.org/keywords/dopamine-agonists","display_name":"dopamine agonists","score":0.9739999771118164},{"id":"https://openalex.org/keywords/dose-response-relationship","display_name":"dose-response relationship","score":0.843999981880188},{"id":"https://openalex.org/keywords/monotherapy","display_name":"monotherapy","score":0.781000018119812},{"id":"https://openalex.org/keywords/unified-parkinson-s-disease-rating-scale","display_name":"Unified Parkinson's Disease Rating Scale","score":0.8460000157356262},{"id":"https://openalex.org/keywords/tolerability","display_name":"tolerability","score":0.7129999995231628},{"id":"https://openalex.org/keywords/sleepiness","display_name":"sleepiness","score":0.9169999957084656},{"id":"https://openalex.org/keywords/adverse-events","display_name":"adverse events","score":0.5289999842643738},{"id":"https://openalex.org/keywords/treatment-efficacy","display_name":"treatment efficacy","score":0.6510000228881836},{"id":"https://openalex.org/keywords/treatment-safety","display_name":"treatment safety","score":0.5569999814033508},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.6209999918937683},{"id":"https://openalex.org/keywords/treatment-withdrawal","display_name":"treatment withdrawal","score":0.5040000081062317}],"concepts":[{"id":"https://openalex.org/C2779989193","wikidata":"https://www.wikidata.org/wiki/Q421304","display_name":"Pramipexole","level":4,"score":0.9675829410552979},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.8988217115402222},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.8765459656715393},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.67709881067276},{"id":"https://openalex.org/C2780304432","wikidata":"https://www.wikidata.org/wiki/Q300989","display_name":"Levodopa","level":4,"score":0.6463326811790466},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.5876089334487915},{"id":"https://openalex.org/C2779734285","wikidata":"https://www.wikidata.org/wiki/Q11085","display_name":"Parkinson's disease","level":3,"score":0.5842783451080322},{"id":"https://openalex.org/C2778258207","wikidata":"https://www.wikidata.org/wiki/Q600203","display_name":"Dopamine agonist","level":4,"score":0.4957188367843628},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.4641384482383728},{"id":"https://openalex.org/C2779034229","wikidata":"https://www.wikidata.org/wiki/Q1077823","display_name":"Somnolence","level":3,"score":0.4579031467437744},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.43273091316223145},{"id":"https://openalex.org/C42219234","wikidata":"https://www.wikidata.org/wiki/Q131130","display_name":"Anesthesia","level":1,"score":0.34003305435180664},{"id":"https://openalex.org/C513476851","wikidata":"https://www.wikidata.org/wiki/Q170304","display_name":"Dopamine","level":2,"score":0.3384624719619751},{"id":"https://openalex.org/C137183658","wikidata":"https://www.wikidata.org/wiki/Q461076","display_name":"Dopaminergic","level":3,"score":0.17796146869659424},{"id":"https://openalex.org/C2779134260","wikidata":"https://www.wikidata.org/wiki/Q12136","display_name":"Disease","level":2,"score":0.1764187514781952},{"id":"https://openalex.org/C204787440","wikidata":"https://www.wikidata.org/wiki/Q188504","display_name":"Alternative medicine","level":2,"score":0.0},{"id":"https://openalex.org/C142724271","wikidata":"https://www.wikidata.org/wiki/Q7208","display_name":"Pathology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000077487","descriptor_name":"Pramipexole","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000368","descriptor_name":"Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D000978","descriptor_name":"Antiparkinson Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004334","descriptor_name":"Drug Administration Schedule","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010300","descriptor_name":"Parkinson Disease","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D012720","descriptor_name":"Severity of Illness Index","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D013844","descriptor_name":"Thiazoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D015233","descriptor_name":"Models, Statistical","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":false},{"descriptor_ui":"D018491","descriptor_name":"Dopamine Agonists","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D052160","descriptor_name":"Benzothiazoles","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":3,"locations":[{"id":"doi:10.1001/jama.1997.03550020057038","doi":"https://doi.org/10.1001/jama.1997.03550020057038","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jama.1997.03550020057038","pdf_url":null,"source":{"id":"https://openalex.org/S172573765","display_name":"JAMA","issn_l":"0002-9955","issn":["0002-9955","0098-7484","1538-3598","2376-8118"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"journal-article"},{"id":"doi:10.1001/jama.278.2.125","doi":"https://doi.org/10.1001/jama.278.2.125","is_oa":false,"landing_page_url":"https://doi.org/10.1001/jama.278.2.125","pdf_url":null,"source":{"id":"https://openalex.org/S172573765","display_name":"JAMA","issn_l":"0002-9955","issn":["0002-9955","0098-7484","1538-3598","2376-8118"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320259","host_organization_name":"American Medical Association","host_organization_lineage":["https://openalex.org/P4310320259"],"host_organization_lineage_names":["American Medical Association"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA: The Journal of the American Medical Association","raw_type":"journal-article"},{"id":"pmid:9214527","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/9214527","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"JAMA","raw_type":"Clinical Trial"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","score":1.0,"id":"https://metadata.un.org/sdg/3"}],"study_designs":[{"display_name":"Randomized Controlled Trial","id":"https://openalex.org/study-designs/randomized-controlled-trial"},{"display_name":"Clinical Trial","id":"https://openalex.org/study-designs/clinical-trial"}],"awards":[{"id":"https://openalex.org/G426531767","display_name":"General Clinical Research Center","funder_award_id":"M01RR000044","funder_id":"https://openalex.org/F4320337375","funder_display_name":"National Center for Research Resources"}],"funders":[{"id":"https://openalex.org/F4320337375","display_name":"National Center for Research Resources","ror":"https://ror.org/04pw6fb54"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2165370634","https://openalex.org/W1994538163","https://openalex.org/W2019300527","https://openalex.org/W1995899111","https://openalex.org/W2158005416","https://openalex.org/W2039405296","https://openalex.org/W2313762846","https://openalex.org/W2020000579","https://openalex.org/W2142359920","https://openalex.org/W2062445990"],"abstract_inverted_index":{"CONTEXT:":[0],"Monotherapy":[1],"with":[2,51,240,256,267,282,299,330],"dopamine":[3,25,65,335],"agonists":[4,66],"may":[5],"be":[6],"useful":[7],"in":[8,149,169,221,236,243,280,297,323,328],"early":[9,52,300],"Parkinson":[10,53],"disease.":[11],"OBJECTIVE:":[12],"To":[13],"evaluate":[14],"dose-response":[15],"relationships":[16],"for":[17,187,191,195,199,204,259,264],"tolerability,":[18],"safety,":[19],"and":[20,88,106,166,189,202,292,325,333],"efficacy":[21,140],"of":[22,48,75,81,122,127,139,175,216,228,316,321],"the":[23,125,130,133,142,150,154,178,181,192,196,200,205,222,260,274,313,319],"synthetic":[24],"agonist":[26],"pramipexole.":[27],"DESIGN:":[28],"Multicenter,":[29],"multidosage,":[30],"parallel-group,":[31],"double-blind,":[32],"placebo-controlled,":[33],"randomized":[34,72],"clinical":[35],"trial.":[36],"SETTING:":[37],"University":[38],"or":[39,60,63,91],"academically":[40],"based":[41],"movement":[42],"disorder":[43],"clinics.":[44],"PATIENTS:":[45],"A":[46,94],"total":[47,151,237],"264":[49],"patients":[50,298],"disease":[54],"(PD)":[55],"who":[56,302],"were":[57,67,71,277],"not":[58,304],"requiring":[59],"receiving":[61,305],"levodopa":[62,331],"other":[64,334],"enrolled.":[68],"INTERVENTION:":[69],"Subjects":[70],"to":[73,146,248,311],"1":[74],"5":[76],"treatment":[77,113,207,253,275],"groups:":[78],"pramipexole":[79,317],"doses":[80],"1.5":[82],"mg/d,":[83,85,87,90],"3.0":[84],"4.5":[86],"6.0":[89],"matching":[92],"placebo.":[93],"6-week":[95],"dosage":[96,184],"escalation":[97],"period":[98,105,109],"was":[99,114,124,141,163,185,210,270],"followed":[100],"by":[101],"a":[102,107,211,233],"4-week":[103],"maintenance":[104],"1-week":[108],"during":[110],"which":[111],"active":[112,252],"withdrawn.":[115],"MAIN":[116],"OUTCOME":[117],"MEASURES:":[118],"The":[119,136,173],"primary":[120,137],"measure":[121,138],"tolerability":[123],"proportion":[126,174],"subjects":[128,176,231,281],"completing":[129,177],"study":[131,179,308],"on":[132,153,180,318],"assigned":[134,183],"treatment.":[135],"change":[143],"from":[144,246],"baseline":[145],"10":[147,226],"weeks":[148,227],"score":[152],"Unified":[155],"Parkinson's":[156],"Disease":[157],"Rating":[158],"Scale":[159],"(UPDRS).":[160],"RESULTS:":[161],"Pramipexole":[162,289],"generally":[164],"safe":[165,291],"well":[167],"tolerated":[168],"this":[170],"10-week":[171],"study.":[172],"originally":[182],"98%":[186],"placebo":[188,261],"81%":[190],"1.5-mg/d,":[193],"92%":[194],"3.0-mg/d,":[197],"78%":[198],"4.5-mg/d,":[201],"67%":[203],"6.0-mg/d":[206,223],"groups.":[208],"There":[209,269],"trend":[212],"toward":[213],"increased":[214],"frequency":[215],"adverse":[217],"experiences,":[218],"particularly":[219],"somnolence,":[220],"group.":[224],"After":[225],"treatment,":[229],"pramipexole-treated":[230],"showed":[232],"20%":[234],"improvement":[235],"UPDRS":[238,284],"scores,":[239],"mean":[241],"improvements":[242],"scores":[244,285],"ranging":[245],"5.9":[247],"7.0":[249],"units":[250,258],"among":[251],"groups,":[254],"compared":[255],"0.9":[257],"group":[262],"(P<.005":[263],"each":[265],"comparison":[266,329],"placebo).":[268],"also":[271],"evidence":[272],"that":[273],"effects":[276],"more":[278],"pronounced":[279],"worse":[283],"at":[286],"baseline.":[287],"CONCLUSIONS:":[288],"is":[290,309],"effective":[293],"as":[294],"short-term":[295],"monotherapy":[296],"PD":[301,324],"are":[303],"levodopa.":[306],"Further":[307],"warranted":[310],"determine":[312],"long-term":[314],"impact":[315],"progression":[320],"disability":[322],"its":[326],"value":[327],"therapy":[332],"agonists.":[336]},"cited_by_api_url":"https://api.openalex.org/works?filter=cites:W4232284669","counts_by_year":[{"year":2026,"cited_by_count":2},{"year":2025,"cited_by_count":1},{"year":2024,"cited_by_count":2},{"year":2023,"cited_by_count":4},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":6},{"year":2019,"cited_by_count":2},{"year":2018,"cited_by_count":6},{"year":2017,"cited_by_count":3},{"year":2016,"cited_by_count":6},{"year":2015,"cited_by_count":4},{"year":2014,"cited_by_count":5},{"year":2013,"cited_by_count":6},{"year":2012,"cited_by_count":6}],"updated_date":"2026-11-16T12:05:36.265796","created_date":"2022-05-12T00:00:00"}
